Cipla Shares Fall 2.63% After Partnering with Eli Lilly to Market Weight-Loss Drug in India

Mumbai, October 24: Cipla Limited share price is trading in the red today, on October 24. As of 11:35 AM, the shares are down by 2.63%, or 45.30 points, and are currently trading at ₹1,601.80. Until now, the shares have traded within a range of ₹1,625.10 and ₹1,625.10. The current traded volume stands at 15.74 lakh shares, with the company’s market cap at ₹1,32,886 crore. The shares have their 52-week high at ₹1,673, and their 52-week low at ₹1,335.

Cipla Limited is an Indian company that manufactures and sells pharmaceuticals in India and globally. The company was established in 1935, and is headquartered in Mumbai, Maharashtra. The shares of the company are listed on NSE with the ticker symbol CIPLA and on BSE with the code 500087.

Key Trigger: Partnering with Eli Lilly to Market Weight-Loss Drug in India

The fall in the share price comes after the company announced that it has partnered with US-based Eli Lilly to market its weight-loss drug in India. Under the collaboration, Eli Lilly will manufacture the product, while Cipla will handle its marketing and distribution under the brand name Yurpeak. The drug will be available as a once-weekly pre-filled injector pen. This is similar to Lilly’s Mounjaro Kwikpen, and will allow doctors to personalise treatment plans for patients.

The company also announced that Yurpeak will be launched in six dosage variants — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, and will be priced at the same amount as Mounjaro.

This comes at a time when Cipla Limited is planning to announce its financial results for the September quarter on October 30. It remains to be seen how the investor sentiment sustains until and after the financial results are announced by Cipla.

REF: https://nsearchives.nseindia.com/corporate/CIPLA_23102025152731_Monsoon_signedRC.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations